771 related articles for article (PubMed ID: 28842247)
1. Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.
Fischer-Valuck BW; Rao YJ; Rudra S; Przybysz D; Germino E; Samson P; Baumann BC; Gay H; Michalski J
J Urol; 2018 Feb; 199(2):416-423. PubMed ID: 28842247
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data.
Audenet F; Waingankar N; Ferket BS; Niglio SA; Marqueen KE; Sfakianos JP; Galsky MD
J Urol; 2018 Nov; 200(5):996-1004. PubMed ID: 29879397
[TBL] [Abstract][Full Text] [Related]
3. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
[TBL] [Abstract][Full Text] [Related]
4. Radical Cystectomy
Haque W; Verma V; Butler EB; Teh BS
Anticancer Res; 2017 Oct; 37(10):5603-5608. PubMed ID: 28982876
[TBL] [Abstract][Full Text] [Related]
5. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.
Fischer-Valuck BW; Rao YJ; Henke LE; Rudra S; Hui C; Baumann BC; Gay HA; Michalski JM
Eur Urol Focus; 2018 Dec; 4(6):900-906. PubMed ID: 28919521
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
Shimizu F; Muto S; Taguri M; Ieda T; Tsujimura A; Sakamoto Y; Fujita K; Okegawa T; Yamaguchi R; Horie S
Int J Urol; 2017 May; 24(5):367-372. PubMed ID: 28281310
[TBL] [Abstract][Full Text] [Related]
7. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
10. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors.
Scrimger RA; Murtha AD; Parliament MB; Venner PM; Hanson J; Houle G; Chetner M
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):23-30. PubMed ID: 11516847
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
12. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation.
Zhong J; Switchenko J; Jegadeesh NK; Cassidy RJ; Gillespie TW; Master V; Nieh P; Alemozaffar M; Kucuk O; Carthon B; Filson CP; Bilen MA; Jani AB
Am J Clin Oncol; 2019 Jan; 42(1):36-41. PubMed ID: 29912804
[TBL] [Abstract][Full Text] [Related]
14. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
Duivenvoorden WC; Daneshmand S; Canter D; Lotan Y; Black PC; Abdi H; van Rhijn BW; Fransen van de Putte EE; Zareba P; Koskinen I; Kassouf W; Traboulsi SL; Kukreja JE; Boström PJ; Shayegan B; Pinthus JH
J Urol; 2016 Dec; 196(6):1627-1633. PubMed ID: 27312316
[TBL] [Abstract][Full Text] [Related]
16. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR; Ballas LK; Niemierko A; Lajkosz K; Kuk C; Miranda G; Drumm M; Mari A; Thio E; Fleshner NE; Kulkarni GS; Jewett MAS; Bristow RG; Catton C; Berlin A; Sridhar SS; Schuckman A; Feldman AS; Wszolek M; Dahl DM; Lee RJ; Saylor PJ; Michaelson MD; Miyamoto DT; Zietman A; Shipley W; Chung P; Daneshmand S; Efstathiou JA
Lancet Oncol; 2023 Jun; 24(6):669-681. PubMed ID: 37187202
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
18. The Association between Mortality and Distance to Treatment Facility in Patients with Muscle Invasive Bladder Cancer.
Ryan S; Serrell EC; Karabon P; Mills G; Hansen M; Hayn M; Menon M; Trinh QD; Abdollah F; Sammon JD
J Urol; 2018 Feb; 199(2):424-429. PubMed ID: 29030318
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
20. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
